Literature DB >> 19047576

Uncritical acceptance of combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease trial results.

Karen A Griffin, Anil K Bidani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19047576      PMCID： PMC2983107          DOI： 10.1161/HYPERTENSIONAHA.108.125062

Source DB:  PubMed          Journal:  Hypertension        ISSN： 0194-911X            Impact factor:   10.190


× No keyword cloud information.
  5 in total

1.  Controversy about COOPERATE ABPM trial data.

Authors:  Anil Bidani
Journal:  Am J Nephrol       Date:  2006       Impact factor: 3.754

Review 2.  Progression of renal disease: renoprotective specificity of renin-angiotensin system blockade.

Authors:  Karen A Griffin; Anil K Bidani
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

3.  Renin-angiotensin blockade and kidney disease.

Authors:  Pantelis A Sarafidis; George L Bakris
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

4.  Recent clinical trials: the good, the bad, and the misleading.

Authors:  Norman M Kaplan
Journal:  Hypertension       Date:  2008-08-11       Impact factor: 10.190

5.  Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial.

Authors:  Naoyuki Nakao; Ashio Yoshimura; Hiroyuki Morita; Masyuki Takada; Tsuguo Kayano; Terukuni Ideura
Journal:  Lancet       Date:  2003-01-11       Impact factor: 79.321
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.